300-OR: Beneficial Effect of the Combination Therapy of Cagrilintide, a Dual Amylin/Calcitonin Agonist, and Tirzepatide, a Dual GLP-1/GIP Agonist, on Body Weight Loss in Obese Rats

Introduction 0.05 vs cagrilintide and P0.001 versus tirzepatide) at the same doses, Reductions in cumulative food intake correlated with weight loss. Combination therapy was superior in decreasing ALT than cagrilintide (P0.001) and tirzepatide (P0.05) and plasma TGs levels were lower compared to the tirzepatide group (P 0.001). Conclusion: Combination therapy at submaximal doses of cagrilintide and tirzepatide achieved significantly greater weight loss and higher reduction in food intake compared to the monotherapy, suggesting the potential opportunity of this combination for further clinical development. Disclosure P. Valdecantos: Research Support; Pep2Tango Therapeutics INC. P. Rada: Research Support; Pep2Tango Therapeutics INC. S. Ghosh: Consultant; Abvance Therapeutics, Akero Therapeutics, Inc., Fractyl Health, Inc., Takeda Pharmaceutical Company Limited. C.M. Rondinone: Board Member; Pep2tango Therapeutics Inc. Stock/Shareholder; Pep2tango Therapeutics Inc. A.M. Valverde: Research Support; Pep2Tango Therapeutics INC. Funding Pep2Tango Therapeutics INC